Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Related Items
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Last modified: December 8, 2017